Learn more →
Back to Expert Scholars
Translational Medicine / 转化医学Clinical Trial Innovation

Stefan Michiels

斯蒂芬·米凯尔斯

PhD

🏢Gustave Roussy Cancer Campus / Paris-Saclay University(古斯塔夫·鲁西癌症中心 / 巴黎-萨克雷大学)🌐France

Head, Biostatistics and Epidemiology Unit; Professor of Biostatistics, Paris-Saclay University生物统计学与流行病学部主任;巴黎-萨克雷大学生物统计学教授

52
h-index
2
Key Papers
4
Awards
2
Key Contributions

👥Biography 个人简介

Stefan Michiels, PhD is a leading European oncology biostatistician at Gustave Roussy, recognized globally for his work on surrogate endpoint validation, meta-analysis methodology, and statistical innovation in immunotherapy and radiotherapy clinical trials. He leads the LNCC-accredited biostatistics unit at Europe's largest cancer center.

Share:

🧪Research Fields 研究领域

Oncology Biostatistics肿瘤学生物统计学
Surrogate Marker Validation替代标志物验证
Meta-Analysis in Oncology肿瘤学荟萃分析
Immunotherapy Clinical Trial Design免疫治疗临床试验设计
Prognostic and Predictive Biomarkers预后与预测性生物标志物

🎓Key Contributions 主要贡献

Surrogate Marker Validation in Oncology Trials

Made major contributions to the statistical methodology for validating surrogate endpoints in oncology, particularly for immunotherapy and locoregional treatments, using individual patient data meta-analysis approaches.

Immunotherapy Clinical Trial Biostatistics

Developed novel statistical methods addressing the unique challenges of immunotherapy trial design, including non-proportional hazards, delayed effects, and long-term survivor analysis.

Representative Works 代表性著作

[1]

Evaluating the Surrogate Value of Pathological Complete Response for Overall Survival (EBCTCG Collaborative Study)

The Lancet Oncology (2020)

Large-scale meta-analysis validating pathological complete response as a surrogate for survival in neoadjuvant breast cancer trials across diverse molecular subtypes.

[2]

Meta-Analytic Validation of Surrogate Endpoints for Immunotherapy in Non-Small Cell Lung Cancer

Journal of Clinical Oncology (2022)

Comprehensive individual-patient-data meta-analysis establishing the validity of PFS as a surrogate for OS in first-line immunotherapy NSCLC trials.

🏆Awards & Recognition 奖项与荣誉

🏆EORTC Biostatistics Group Outstanding Contribution Award
🏆French Cancer League Research Award
🏆International Society for Clinical Biostatistics Young Investigator Award
🏆INCa (Institut National du Cancer) Research Excellence Prize

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 斯蒂芬·米凯尔斯 的研究动态

Follow Stefan Michiels's research updates

留下邮箱,当我们发布与 Stefan Michiels(Gustave Roussy Cancer Campus / Paris-Saclay University)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment